articleTop 1% cited

Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease

Gastrointestinal Endoscopy · 2006 · Vol. 63(3) · pp. 433–442

Paul Rutgeerts✉(Atlanta Gastroenterology Associates)Robert H. Diamond(Hôpital Claude Huriez)Mohan Bala(University of Chicago Medical Center)Allan Olson(University of Chicago Medical Center)Gary R. Lichtenstein(Cleveland Clinic)Weihang Bao(Atlanta Gastroenterology Associates)Kamlesh B. Patel(Universitair Ziekenhuis Leuven)Douglas C. Wolf(University of Chicago Medical Center)Michael Safdi(Hôpital Claude Huriez)Jean‐Frédéric Colombel(Hôpital Claude Huriez)Bret A. Lashner(Cleveland Clinic)Stephen B. Hanauer(Atlanta Gastroenterology Associates)

View via DOI Publisher page

Inflammatory Bowel Disease Autoimmune and Inflammatory Disorders Microscopic ColitisMedicineInfliximabCrohn's diseaseDiseaseDermatologySurgeryGastroenterologyInternal medicine

MeSH terms

InfliximabAdultAntibodies, MonoclonalColonCrohn DiseaseDrug Administration ScheduleFemaleFollow-Up StudiesGastrointestinal AgentsHumansIleumIntestinal MucosaMaleSeverity of Illness IndexUlcer

Citations

547

FWCI

26.38

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target